Introduction
============

Breast cancer is the most common cancer in the world ([@B20]). In India, according to the National Cancer Registry Programme ([@B59]), incidence of breast cancer ranks amongst the top in the following individual registries across India: Delhi (41.0%), Chennai (37.9%), Bangalore (34.4%) and Thiruvananthapuram district (33.7%). In the state of Punjab, the highest incidence rate of breast cancer has been reported in districts of Bathinda (37.3%), followed by Mohali (34.3%), Patiala (32.5%) and Faridkot (31.5%) ([@B58]), with increasing frequency of sporadic breast cancer being reported from Amritsar ([@B8]).

One of the well-studied genes that has been associated with breast cancer, *BRCA1* (MIM 113705), is located at the chromosomal position 17q21 and contains 24 exons ([@B34]). It encodes a multi-domain protein BRCA1, which has four major domains: a RING domain, the BRCA1 serine domain and two BRCA1 C terminus (BRCT) domains ([@B16]). BRCA1 interacts with a variety of other proteins to carry out multiple functions at the cellular level, like controlling the cell cycle, DNA damage repair, regulation of transcription, replication, recombination and chromatin hierarchical control ([@B37]).

Mutations in *BRCA1* and *BRCA2* genes are the most susceptible causes amongst the genetic risk factors that play a crucial role in familial breast cancer ([@B35]). A frequency of 2.9-24% of *BRCA1/2* mutations has been reported in familial breast cancer patients of South India ([@B47]). However, the reported frequency of mutations in *BRCA2* is remarkably lower than in *BRCA1* in India ([@B28]).

Populations of Caucasian and Indoscythian mixed racial ancestry inhabit the state of Punjab in North India ([@B10]). Therefore, the *BRCA1* variants were chosen for the study considering their prevalence in similar Caucasian and South Asian populations in other parts of the world. The four variants of *BRCA1* \[c.190T\>C (p.Cys64Arg), 1307delT, g.5331G\>A (p.G1738R) and c.2612C\>T (p.Pro871Leu)\] were investigated in the current study. The variant c.2612C\>T (p.Pro871Leu) is a non-synonymous polymorphism of *BRCA1* that leads to the substitution of proline by leucine at position 871, a region where recombinase RAD51 interacts with BRCA1 to aid homologous recombination ([@B33]). The T allele has been reported to show an association with breast cancer risk in Chinese populations ([@B55]) though some studies have reported no significant association between the p.Pro871Leu variant of *BRCA1* and breast cancer risk. The 1307delT variant of *BRCA1*, present in codon 396 of exon 11, causes a frameshift mutation that introduces a premature stop codon at amino acid residue 409 and leads to protein truncation. It was reported in the South Indian population ([@B19]). The c.1907T\>C variant of *BRCA1* is a missense mutation present in exon 5 (Cys64Arg). Molecular modelling indicated that the substitution of cysteine with an arginine probably disturbs the structure of the BRCA1 RING finger domain, which is responsible for the interaction with BARD1 and essential for the tumor-suppressor activity of the BRCA1-BARD1 complex ([@B26]). g.5331G\>A (p.G1738R) is a missense variant of *BRCA1* that affects the binding affinity of the protein by destabilizing it ([@B53]; [@B21]). It has been reported as a pathogenic mutation (Chenevix-Trench *et al.*, 2006; [@B27]).

Although a few common variants of *BRCA1* have been repeatedly reported from South India, the dissimilarity between the populations of North India: Caucasians, Scythians and Indo-Europeans ([@B10]; [@B39]) and South India: Dravidian ([@B39]), led us to consider studying the variants in North India. Thus, the current study aimed to screen the Punjabi population from Amritsar and adjoining regions of Punjab, North India, for the four variants of *BRCA1* \[c.190T\>C (p.Cys64Arg), 1307delT, g.5331G\>A (p.G1738R) and c.2612C\>T (p.Pro871Leu)\] to investigate their association with breast cancer risk. Identifying *BRCA1* polymorphisms that are associated with breast cancer risk can also be further explored for involvement in the therapy response of patients. *BRCA1* c.190T\>C (p.Cys64Arg) and g.5331G\>A (p.G1738R) have never been reported from India in any of the studies so far. Also, these four variants together have not been investigated in Indian patients in any previous study.

Subjects and Methods
====================

Study subjects
--------------

In this case-control study, patients were selected from a tertiary care hospital, Sri Guru Ram Das Institute of Medical Sciences and Research, Vallah, Amritsar, Punjab. The majority of the patients (81%) belonged to the Majha region of Punjab, i.e., to the Amritsar district (34%) and its adjoining districts of Gurdaspur (32%) and Tarn Taran (15%). The rest of the patients belonged to the districts of Jalandhar (5%), Kapurthala (5%), Hoshiarpur (4%), Pathankot (3%), Ferozpur (2%) and Mansa (1%). Three patients, each belonging to the states of Jammu and Kashmir, Himachal Pradesh and Uttar Pradesh, were also included. A total of 255 (5 males and 250 females) clinically confirmed breast cancer patients and 255 age and gender matched normal healthy individuals were recruited in the present study between January 2013 and March 2017. Patients who had received chemotherapy, radiotherapy or blood transfusion before surger, or had previous history of any malignancy were excluded from the study. Controls were biologically unrelated to cancer patients and were from the same geographical region as the patients. Individuals in the control group had no family history of any cancer or any other chronic disease. This study was undertaken after approval by the institutional ethics committee of Guru Nanak Dev University, Amritsar, Punjab, India. After informed consent, as per tenets of the Declaration of Helsinki,a5 mL peripheral venous blood sample was collected in an EDTA vial from each subject.

DNA isolation and screening of *BRCA1* variants
-----------------------------------------------

Genomic DNA was extracted from peripheral blood lymphocytes by a standard phenol-chloroform method ([@B2]). Four variants of *BRCA1*, c.190T\>C (p.Cys64Arg), 1307delT, g.5331G\>A (p.G1738R) and c.2612C\>T (p.Pro871Leu) were screened by a PCR-RFLP method using published primer sequences ([@B19]; [@B26]; [@B55]).

The PCR assays were set up in a 15 μL reaction volume containing 50 ng of DNA, 1X *Taq* buffer with 1.5 mM MgCl2, 0.3 μL dNTPs mixture (Bangalore GeNei), 6 pmol of each primer (Sigma, St. Louis, MO, USA), 1U *Taq* DNA Polymerase (Bangalore GeNei). The PCR conditions were: an initial denaturation at 95 °C for 5 min, followed by 35 cycles with denaturation at 95 °C for 45 s, annealing at 58 °C for 30 s and extension at 72 °C for 45 s, and a final extension step at 72 °C for 10 min, run in a Mastercycler gradient (Eppendorf, Germany) machine. A negative control without template DNA was run in each reaction to check for contamination. The PCR products were analysed on 2% ethidium bromide-stained agarose gels. Amplified products were digested with the respective restriction enzymes following the manufacturer's instructions (New England Biolabs, Beverly, MA), details of which are shown in [Table 1](#t1){ref-type="table"}. The restriction digestion reaction products were also analysed on 2.5% ethidium bromide-stained agarose gels. The genotype was assigned to each sample according to the size of the fragments obtained after digestion ([Table 1](#t1){ref-type="table"}). Genotyping was performed without knowing the status of the subjects.

###### Details of analyzed *BRCA1* variants and restriction conditions used for genotyping.

  S. No.   Variant                    PCR product size (bp)   Restriction enzyme used   Digestion temperature   Fragment size (bp) after digestion   Alleles
  -------- -------------------------- ----------------------- ------------------------- ----------------------- ------------------------------------ ---------
  1\.      c.190T\>C (p.Cys64Arg)     193 bp                  *SnaB*I                   37 °C                   193                                  T
                                                                                                                124 and 69                           C
  2\.      g\. 5331G\>A (p.G1738R)    233 bp                  *BsaX*I                   37 °C                   112, 91 and 30                       G
                                                                                                                233                                  A
  3\.      1307delT                   151 bp                  *Dde*I                    37 °C                   151                                  WT
                                                                                                                96 and 55                            MUT
  4\.      c.2612C\>T (p.Pro871Leu)   125 bp                  *Hpa*II                   37 °C                   99 and 26                            C
                                                                                                                125                                  T

WT - wild type; MUT - mutant.

Statistical analysis
--------------------

A chi-square test was used to test for Hardy-Weinberg Equilibrium (HWE) and difference of genotype and allele frequencies between the breast cancer patients and normal controls. For determining the association between *BRCA1* variants with breast cancer risk, the odds ratio (OR) with 95% confidence interval (CI) was calculated. A genetic model analysis was done to check for an association of the BRCA1 variants with breast cancer risk. A value of p ≤ 0.05 was considered statistically significant. Statistical analysis was performed by using SPSS (Version 20.0; SPSS, Inc).

Results
=======

The present study recruited 255 clinically and histopathologically confirmed breast cancer patients and 255 healthy controls. Out of the 255 patients, 250 (98%) were females and 5 (2%) were males. The mean age of the patients was 50.7 ± 11.43 years (range 27-85 years) and that of controls was 48.56 ± 14.26 (range 17-90 years). The frequency of patients diagnosed with stage I, stage II, stage III and stage IV breast cancer were 14.9%, 46.8%, 25.5% and 12.8%, respectively ([Table 2](#t2){ref-type="table"}). Out of these, 40% of the patients were triple negative for the receptor status. The majority of the patients had sporadic breast cancer (78.8%), while 7.5% reported a history of breast cancer in their family ([Table 3](#t3){ref-type="table"}). Another 13.7% of the patients had a history of cancer of other sites. Hence, 21.2% of the patients had a family history of any type of cancer.

###### Clinical profile of breast cancer patients.

  Parameter                    Total n (%)   Females n (%)   Males n (%)
  ---------------------------- ------------- --------------- -------------
  Stage                                                      
  I                            35(14.9)      35(15.2)        0(0)
  II                           110(46.8)     105(46.7)       5(100)
  III                          60(25.5       60(26.1)        0(0)
  IV                           30(12.8)      30(13)          0(0)
  Breast side                                                
  Left                         116(47.2)     113(46.9)       3(60)
  Right                        121(49.2)     120(49.8)       1(20)
  Bilateral                    9(3.6)        8(3.3)          1(20)
  Histological Type                                          
  DCIS                         6(2.7)        6(2.8)          0(0)
  DCIS-Papilary                3(1.3)        3(1.4)          0(00
  IDC                          205(91.9)     200(91.7)       5(100)
  IDC-Mucinous                 5(2.2)        5(2.2)          0(0)
  IDC-Medulllary               1(0.5)        1(0.5)          0(0)
  IDC-Pagets                   1(0.5)        1(0.5)          0(0)
  Invasive Lobular Carcinoma   2(0.9)        2(0.9)          0(0)

n: number of subjects

###### Breast cancer patients with family history of cancer.

  Category                   Cases   \% of Total Cases
  -------------------------- ------- -------------------
  Sporadic cases             201     78.8
  Familial cases             54      21.2
  History of breast cancer           
  1^st^ Relatives            11      4.3
  2^nd^ Relatives            5       2.0
  3^rd^ Relatives            3       1.2
  History of other cancer            
  1^st^ Relatives            23      9.0
  2^nd^ Relatives            12      4.7
  3^rd^ Relatives            0       0

The genotype and allele frequencies of the four analysed *BRCA1* variants in cases and controls are shown in [Table 4](#t4){ref-type="table"}. For the 3 variants c.190T\>C (p.Cys64Arg), 1307delT and c.5331G\>A (p.G1738R) all the patients and controls had the wild-type genotype ([Figures S1](#suppl01){ref-type="supplementary-material"}-[S4](#suppl04){ref-type="supplementary-material"}). The observed genotype frequencies for the c.2612C\>T polymorphism were in HWE in the controls (*p*=0.11). The frequency of the CC, CT and TT genotypes of c.2612C\>T polymorphism were 14.5% vs. 15.7%, 59.6% vs. 53.7% and 25.9% vs 30.6%, respectively, in breast cancer patients and control individuals. No association was observed between the breast cancer risk and the CT (OR = 1.19, 95% CI: 0.73-1.98, *p*=0.48) and TT (OR = 0.91, 95% CI:0.53-1.59, *p*=0.75) genotypes. The c.2612 C\>T polymorphism did not show an association with breast cancer in any of the genetic models ([Table 4](#t4){ref-type="table"}). The T allele frequency was higher than that of the C allele in both patients and controls, but the difference between patients and controls was not significant (*p*=0.57). The difference in the frequency distribution of the C and T alleles in breast cancer patients with involvement of left, right or bilateral sides was statistically non-significant (*p*=0.55). This difference was also not significant (*p*=0.60) amongst patients at different stages of breast cancer.

###### Association analyses of *BRCA1* variants with breast cancer risk.

  Variant                                Genotype   Patients n (%)   Controls n (%)   OR (95%CI)        *p*-value
  -------------------------------------- ---------- ---------------- ---------------- ----------------- -----------
  c.190T\>C (p.Cys64Arg)                 TT         255(100)         255(100)         \-                NC
                                         TC         0                0                                  
                                         CC         0                0                                  
  1307delT                               WT/WT      255(100)         255(100)         \-                NC
                                         WT/MUT     0                0                                  
                                         MUT/MUT    0                0                                  
  c.5331G\>A (p.G1738R)                  GG         255(100)         255(100)         \-                NC
                                         GA         0                0                                  
                                         AA         0                0                                  
  c.2612 C\>T (p.Pro871Leu)              CC         37(14.5)         40(15.7)         1 (ref)           
                                         CT         152(59.6)        137(53.7)        1.19(0.73-1.98)   0.48
                                         TT         66(25.9)         78(30.6)         0.91(0.53-1.59)   0.75
                                         Allele                                                         
                                         C          226(44.3)        217(42.5)        1 (ref)           
                                         T          284(55.7)        293(57.5)        0.93(0.73-1.19)   0.57
  Genetic Models                                                                                        
  Dominant Model CT/TT vs CC                                                          1.10(0.67-1.78)   0.71
  Co-dominant Model TT vs CT =CT vs CC                                                0.92(0.70-1.20)   0.54
  Recessive Model TT vs CC/CT                                                         0.79(0.54-1.17)   0.24

n: number of subjects; OR: odds ratio; CI: confidence intervals; NC: not calculated.

To evaluate the relation between the parameters like age at diagnosis, menopausal history, habitat, diet and BMI with the *BRCA1* p.Pro871Leu variant, the cases and controls were stratified according to the aforementioned parameters. We found no significant difference in the genotypic frequencies among patients and controls. However, there was a significant difference in C and T allele frequencies among cases and controls for parameters like age at diagnosis in the group 36-50 years (OR = 0.47, 95% CI = 0.32-0.70, *p*=0.00), frequency of premenopausal women (OR = 0.56, 95% CI = 0.36-0.87, *p*=0.01), frequency of post-menopausal women (OR = 0.65, 95% CI = 0.46-0.90, p=0.01), rural habitat (OR = 0.51, 95% CI = 0.37-0.87, *p*=0.000), vegetarian diet (OR = 0.61, 95% CI = 0.44-0.85, *p*=0.003) and obesity (BMI ≥ 23 kg/m2) (OR = 0.62, 95% CI = 0.46-0.84, *p*=0.002) ([Table 5](#t5){ref-type="table"}).

###### Correlation of *BRCA1* p.Pro871Leu variant with demographic parameters in subjects.

  Parameter                  Genotypes   OR (95% CI)   *p*-value   Allele      OR (95% CI)        *p*-value                                                                     
  -------------------------- ----------- ------------- ----------- ----------- ------------------ ----------- ----------- ----------- ----------- ----------- ----------------- -----------
  Age at diagnosis (years)                                                                                                                                                      
  ≤ 35                       5(13.9)     26(10.9)      3(11.1)     45(20)      0.35(0.08-1.57)    0.17        26(11.7)    36(12.7)    34(19.9)    62(18.6)    0.76(0.39-1.46)   0.41
  36-50                      15(41.7)    118(49.6)     8(29.6)     96(42.7)    0.66(0.27-1.61)    0.36        106(47.5)   118(41.7)   62(36.3)    146(43.9)   0.47(0.32-0.70)   **0.00**
  51-65                      13(36.1)    77(32.4)      6(22.2)     66(29.3)    0.54(0.19-1.5)     0.24        73(32.7)    107(37.8)   45(26.3)    99(29.7)    0.67(0.42-1.06)   0.08
  ≥ 66                       3(8.3)      17(7.1)       10(37.1)    18(8.0)     3.15(0.74-13.45)   0.12        18(8.1)     22(7.8)     30(17.5)    26(7.8)     1.41(0.62-3.19)   0.41
  Menstrual history                                                                                                                                                             
  premenopausal              12(35.3)    66(32.0)      6(26.1)     88(42.3)    0.38(0.13-1.05)    0.06        71(33.3)    85(31.8)    60(39.5)    128(41.3)   0.56(0.36-0.87)   **0.01**
  postmenopausal             22(64.7)    140(68.0)     17(73.9)    120(57.7)   1.46(0.56-3.18)    0.76        142(66.7)   182(68.2)   92(60.5)    182(58.7)   0.65(0.46-0.90)   **0.01**
  Habitat                                                                                                                                                                       
  rural                      27(77.1)    163(76.9)     16(61.5)    162(73)     0.60(0.31-1.15)    0.12        167(77.0)   213(76.9)   101(60.8)   255(77.3)   0.51(0.37-0.69)   **0.000**
  urban                      8(22.9)     49(23.1)      10(38.5)    60(27)      1.02(0.37-2.78)    0.97        50(23.0)    64(23.1)    65(39.2)    75(22.7)    0.68(0.67-1.82)   0.68
  Diet                                                                                                                                                                          
  vegetarian                 24(68.6)    136(64.5)     16(61.5)    134(61.5)   0.68(0.34-1.33)    0.26        146(67.3)   174(63.3)   102(61.8)   198(61.3)   0.61(0.44-0.85)   **0.003**
  non-vegetarian             11(31.4)    75(35.5)      10(38.5)    84(38.5)    0.81(0.33-2.02)    0.65        71(32.7)    101(36.7)   63(38.2)    125(38.7)   0.72(0.47-1.10)   0.13
  BMI                                                                                                                                                                           
  non-obese                  7(20.6)     60(29.9)      5(19.2)     42(19.0)    1.02(0.30-3.43)    0.97        56(26.9)    78(29.8)    30(18.1)    64(19.5)    0.65(0.38-1.14)   0.13
  obese                      27(79.4)    141(70.1)     21(80.8)    179(81.0)   0.61(0.33-1.23)    0.12        152(73.1)   184(70.2)   136(81.9)   264(80.5)   0.62(0.46-0.84)   **0.002**

n: number of subjects; OR: odds ratio; CI: confidence intervals; NC: not calculated; *p*\<0.05 (significance).

Discussion
==========

In the present case-control study, we assessed the relationship of c.190T\>C (p.Cys64Arg), 1307delT, g.5331G\>A (p.G1738R) and c.2612C\>T variants of *BRCA1* with breast cancer risk. The variants p.Cys64Arg and p.G1738R have never been reported from any Indian study so far, and also c.2612C\>T had not yet been reported from India at the time when the present study was undertaken. It has been only recently reported from a population of West India (Gujarat), where 32 polymorphisms and two novel mutations in *BRCA1* were found in 35 breast cancer patients by an NGS method ([@B41]). Among these, c.2612C\>T was found in six out of the 35 patients.

The c.190T\>C variant has been reported as a pathological mutation in families with HBOC (history of breast and ovarian cancer) in Polish ([@B24]), Italian ([@B52]; [@B11]), Brazilian ([@B18]), French ([@B7]) and Japanese ([@B4]) populations. A few *in-vitro* studies have also revealed its deleterious effects ([@B17]; [@B3]). In the present study, only the wild type genotype (TT) of c. 190T\>C was found in all the patients and controls from Amritsar.

The 1307delT variant was first time reported in a South Indian family with Dravidian ancestry having breast cancer ([@B19]). The South Indian population represents a racial compositon different from that of North India. In the present study all the patients and controls, which were from the Northwest part of India, with Caucasian and Indoscythian ancestry ([@B39]), had the wild type genotype for this variant.

The g.5331G\>A (p.G1738R) missense mutation has been repeatedly found in Greek families with breast cancer ([@B9]; [@B5]; [@B31]), ovarian cancer ([@B45]) or both ([@B30]; Karami and Mehdipour, 2013). It is also reported to be a deleterious mutation in *in-vitro* assays ([@B12]; [@B15]). None of the patients or controls in the present study carried this mutation.

The c.2612C\>T (p.Pro871Leu) non-synonymous SNP causes an amino acid change from proline to leucine at position 871 in the BRCA1 protein. The previous published studies give contradictory reports on the role of p.P871L and the risk for various types of cancers. The wild type genotype (CC) was associated with increased risk of gastric cancer ([@B49]), esophageal squamous cell carcinoma (ESCC) ([@B56]) and non-Hodgkin Lymphoma (NHL) ([@B14]), but not associated with thyroid carcinoma ([@B54]) and ovarian cancer ([@B51]; [@B6]). In a recent meta-analysis ([@B55]), the p.Pro871Leu polymorphism was linked to decreased risk of various cancers like ESCC, cervical cancer, gastric cancer and NHL among Asians. But some studies from Chinese populations have reported significant associations between the *BRCA1* p.Pro871Leu variant and breast cancer, where the CT genotype provides increased risk to breast cancer in these populations ([@B23]; [@B50]). The homozygous variant TT genotype has also been reported to be associated with reduction in glioblastoma risk in Caucasians ([@B13]) and NHL risk in Korea ([@B29]). The T allele of the p.Pro871Leu polymorphism has been shown to be linked with miR-628 dependent BRCA1 reduction, indicating that cells with the T allele would express higher BRCA1 as compared to those with the C allele ([@B36]). In the present study, none of the genotypes of this variant were found to be associated with breast cancer risk. Similar findings have been reported in a Czech population ([@B44]), where no association was reported. Meta-analyses carried out in 2014 ([@B38]) and 2017 ([@B37]) reported no association of the p.Pro871Leu polymorphism and breast cancer risk. Contradictory results have also been reported for the *BRCA1* 871L allele, as significantly associated with increased risk of breast cancer in a Polish population ([@B43]). An association of the TT genotype with reduced breast cancer risk in Chinese has also been reported ([@B57]).

When assessed for response to therapy, p.Pro871Leu showed no association with either advanced phases of CML or treatment response ([@B22]). The CT/TT genotypes have been reported to be associated with ovarian cancer progression in non-African American patients, but not with progression-free survival (PFS) and overall survival (OS) in patients treated with cisplatin and paclitaxel ([@B46]). The TT genotype has been reported to not only contribute to increased breast cancer risk associated with combined estrogen monotherapy in postmenopausal women in Germany ([@B1]), but also with recurrence of TNBC after radiotherapy in Han Chinese ([@B42]).

Understanding of the biological mechanisms underlying breast cancer predisposition by genomic profiling can help to define molecular targets for chemoprevention and biomarkers of breast cancer risk. India is the second most populous country in the world, but not much information on *BRCA1* is available as of now. The 185delAG variant has been found to be the most common mutation in BRCA1 in India, as revealed by a few reported studies of limited sample sizes (range 19 - 204). It has been found in variable frequencies in the studied groups from North India: 7.14% ([@B32]), 0.49% ([@B40]) and South India: 7 out of 19 members in a single family study ([@B25]), 54.5% ([@B48]) and 16.4% ([@B47]). The present study is the first report providing baseline data on four variants of *BRCA1* from the Amritsar and adjoining regions of Punjab, Northwest India. The three mutations \[c.190T\>C (p.Cys64Arg), 1307delT and g.5331G\>A (p.G1738R)\], which have been widely known as pathogenic in Caucasians, have no mutant genotype in the studied population. For the c.2612C\>T polymorphism also, the T allele frequency was slightly higher than that of the C allele, and there was a preponderance of the CT genotype, but no association with the breast cancer risk. A marked variation in the distribution of p.Pro871Leu in the Northwest Indian population from the previously reported populations of South India has been observed. The present study indicates the need of screening Indian populations for other mutations/variants in *BRCA1* gene for identifying breast cancer risk and possible targets for therapy.
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